

ACT BIOTECH Broadens Pipeline with Advance of Two New Cancer Drugs

FOR IMMEDIATE RELEASE 7AM EDT / 1PM CET ON NOVEMBER 18, 2010 – Berlin, Germany, November 18th, 2010 – ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, yesterday presented new data from two late pre-clinical cancer drug candidates, further broadening their pipeline of targeted cancer therapeutics.

ACTB1003 is a first-in-class, oral kinase inhibitor with multiple modes of action against cancer. ACTB1003 disrupts cell growth signals through inhibition of all four FGF receptors, induces apoptosis through inhibition of the RSK and S6K kinases, and has potent anti-angiogenic properties through the targeting of VEGFR and TIE2. Data presented yesterday demonstrates potential for additive or synergistic antitumor efficacy not only within each pathway but across multiple pathways, with one drug, which may overcome mechanisms of resistance. Earlier in 2010 the US Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application for ACTB1003, and phase 1 trials are scheduled to begin shortly.

ACTB1010 is a best-in-class, oral aurora A&B kinase inhibitor. Because of exquisite selectivity and oral dosing flexibility, ACTB1010 has been able to demonstrate excellent efficacy in pre-clinical models without unwanted side effects common to other compounds in the class. In addition, ACTB1010 has demonstrated strong tumor shrinkage in solid tumor models, as well as complete regressions in leukemia models. Data presented yesterday demonstrates the ability to use schedule and dose optimization to achieve in vivo activity without myelosuppression. IND enabling toxicology studies for ACTB1010 have begun.

These compounds were presented on Wednesday, November, 17, at the 22nd EORTC-NCI-AACR symposium on “Molecular targets and Cancer Therapeutics”, Berlin, Germany.

Wolf D. Busse, Chief Executive Officer and President of ACT Biotech commented, “Along with Telatinib, our phase 3 ready agent for first-line gastric cancer, ACTB1003 and ACTB1010 expand ACT Biotech’s deep and varied pipeline of novel anti-cancer drugs.”

About ACT Biotech, Inc

ACT Biotech (www.actbiotech.com) is a San Francisco-based, privately-held biopharmaceutical company focused on the development and commercialization of targeted cancer drugs. In addition to ACTB1003 and ACTB1010, the Company’s pipeline includes Telatinib, a potent oral kinase inhibitor that selectively targets VEGFR, PDGFR and KIT receptor tyrosine kinases. ACT recently announced positive phase 2 data in first-line gastric cancer with Telatinib, and phase 3 planning activities are underway in preparation for the initiation of pivotal studies in 2011 and the filing for marketing authorization in 2014. Other pipeline products include an ABL tyrosine kinase inhibitor program targeting the T315I mutant enzyme in pre-clinical development. ACT Biotech is backed by NGN Capital of New York, NY; Greenwich, CT; and Heidelberg, Germany.

Contact:

Robert Jacks, VP Corporate Development

robert.jacks@actbiotech.com

415-230-3907

#####